Dexamethasone sodium phosphate
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Ataxia Telangiectasia
Conditions
Ataxia Telangiectasia
Trial Timeline
Jun 24, 2024 → Dec 17, 2025
NCT ID
NCT06193200About Dexamethasone sodium phosphate
Dexamethasone sodium phosphate is a phase 3 stage product being developed by Quince Therapeutics for Ataxia Telangiectasia. The current trial status is completed. This product is registered under clinical trial identifier NCT06193200. Target conditions include Ataxia Telangiectasia.
What happened to similar drugs?
0 of 12 similar drugs in Ataxia Telangiectasia were approved
Approved (0) Terminated (1) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06664853 | Phase 3 | Terminated |
| NCT06193200 | Phase 3 | Completed |
Competing Products
20 competing products in Ataxia Telangiectasia